海隆控股(01623.HK)董事會主席兼控股股東張軍增持100萬股
格隆匯4月7日丨海隆控股(01623.HK)公佈,公司董事會獲執行董事、董事會主席兼公司控股股東張軍先生告知,於2020年4月7日,Hilong Group Limited(由Standard Chartered Trust (Singapore) Limited作為張先生信託的受託人間接全資擁有的公司)於市場上收購100萬股公司股份,總代價為41.23萬港元(相當於平均價每股0.4123港元)。
收購事項充分展現張先生對公司的整體發展前景及增長潛力充滿信心。緊隨收購事項後,張先生於合共9.98億股股份中擁有權益,相當於公司於本公告日期已發行股本總額約58.84%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.